CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 
 

LGVN's Capital Expenditures Growth by Quarter and Year

Longeveron Inc 's Capital Expenditures results by quarter and year




LGVN Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 1.15 0.00 0.00
III Quarter September 0.48 0.03 0.00 0.00
II Quarter June 0.10 0.12 0.00 0.00
I Quarter March 0.12 0.00 0.00 0.00
FY   0.70 1.30 0.00 0.00



LGVN Capital Expenditures third quarter 2022 Y/Y Growth Comment
Longeveron Inc achieved in the third quarter 2022, above Company average Capital Expenditures surge of 1510% year on year, to $ 0.48 millions.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Capital Expenditures growth. While Longeveron Inc ' s Capital Expenditures doubling of 1510% ranks overall at the positon no. 56 in the third quarter 2022.




LGVN Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September 1510 % - - -
II Quarter June -16.67 % - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Longeveron Inc 's third quarter 2022 Capital Expenditures $ 0.48 millions LGVN's Income Statement
Longeveron Inc 's third quarter 2021 Capital Expenditures $ 0.03 millions Quarterly LGVN's Income Statement
New: More LGVN's historic Capital Expenditures Growth >>


LGVN Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 3733.33 % - -
III Quarter September 383 % -75 % - -
II Quarter June -16.67 % - - -
I Quarter March -89.57 % - - -
FY (Year on Year)   - - - -




Capital Expenditures third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #22
Overall #56

Capital Expenditures Y/Y Growth Statistics
High Average Low
1363.64 % 670.93 % -21.77 %
(Sep 30 2022)   (Jun 30 2022)
Capital Expenditures third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #22
Overall #56
Capital Expenditures Y/Y Growth Statistics
High Average Low
1363.64 % 670.93 % -21.77 %
(Sep 30 2022)   (Jun 30 2022)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Longeveron Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
3393.94 % 722.19 % -89.77 %
(Dec 31 2021)  


LGVN's III. Quarter Q/Q Capital Expenditures Comment
Longeveron Inc achieved in the III. Quarter 2022 below company average Capital Expenditures doubling of 383% quarter on quarter, to $ 0.48 millions.

Albeit the III. Quarter 2022 LGVN's results were lower than the average , this was yet encouraging story, as the current surge, outshines the -75% surge in the same quarter a year ago

Within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Longeveron Inc 's Capital Expenditures growth quarter on quarter, overall rank is 111.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #41
Overall #111
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #41
Overall #111
Capital Expenditures Q/Q Growth Statistics
High Average Low
3393.94 % 722.19 % -89.77 %
(Dec 31 2021)  


LGVN's III. Quarter Q/Q Capital Expenditures Comment
Longeveron Inc achieved in the III. Quarter 2022 below company average Capital Expenditures doubling of 383% quarter on quarter, to $ 0.48 millions.

III. Quarter 2022 LGVN's performance seem to be a mixed bag, even if beneath the ordinary rise of 722.19 %, yet it shows a quite improvement compare to the -75% in the III. Quarter a year ago Reyansh Patel, Healthcare sector veteran mentioned.

Within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Longeveron Inc 's Capital Expenditures growth quarter on quarter, overall rank is 111.


Longeveron Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 1.85 $ 1.40 $ 0.12 $ 1.31 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) 32.12 % 1087.29 % -90.99 % - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 387 # 28 # 3476 # #




Cumulative Capital Expenditures growth Comment
Longeveron Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 1510% year on year, to $ 2 millions if the fiscal year would have ended in Sep 30 2022.
Longeveron Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 0% and higher than % growth in Jun 30 2022. And, Longeveron Inc realized the fastest Capital Expenditures growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Jun 30 2022 increase was slower at 32.12 % from $1.4 millions achieved in the period from Jun 30 2022 to Sep 30 2021.
There is drop-off developing, more noticeable as we look at average Q/Q TTM Capital Expenditures advancement that is stronger at342.81% Reyansh Patel wrote.
The momentum is even stronger sequentially exhibited at 32.12 % jump from $1.4 millions in twelve months ending a quarter before.

Longeveron Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1087.29 %
342.81 %
-90.99 %
(Jun 30 2022)  

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 100
S&P 500 # 387
Cumulative Capital Expenditures growth Comment
Longeveron Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 1510% year on year, to $ 2 millions if the fiscal year would have ended in Sep 30 2022.
Longeveron Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 0% and higher than % growth in Jun 30 2022. And, Longeveron Inc realized the fastest Capital Expenditures growth, in Major Pharmaceutical Preparations industry.
But sequential growth rate was beneth at 32.12 % from $1.4 millions achieved in twelve months ending a quarter before.
It appears to be slowdown developing, more evident if you pay attention to the usual sequential historic increase which is better at342.81%.
The growth was much stronger from twelve months ended Jun 30 2022 showed at 32.12 % increase from $1.4 millions in twelve months ending a quarter Jun 30 2022.

Longeveron Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1087.29 %
342.81 %
-90.99 %
(Jun 30 2022)  


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 42
Sector # 100
S&P 500 # 387




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
LGVN's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for LGVN's Competitors
Capital Expenditures Growth for Longeveron Inc 's Suppliers
Capital Expenditures Growth for LGVN's Customers

You may also want to know
LGVN's Annual Growth Rates LGVN's Profitability Ratios LGVN's Asset Turnover Ratio LGVN's Dividend Growth
LGVN's Roe LGVN's Valuation Ratios LGVN's Financial Strength Ratios LGVN's Dividend Payout Ratio
LGVN's Roa LGVN's Inventory Turnover Ratio LGVN's Growth Rates LGVN's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2022
Encision Inc 2,603.25%$ 2,603.248 millions
Prophase Labs Inc 2,538.10%$ 2,538.095 millions
Lifeloc Technologies Inc 2,422.53%$ 2,422.529 millions
Kezar Life Sciences Inc 2,219.23%$ 2,219.231 millions
Diamedica Therapeutics Inc 2,050.00%$ 2,050.000 millions
Aquestive Therapeutics Inc 1,968.67%$ 1,968.675 millions
Sensus Healthcare Inc 1,900.00%$ 1,900.000 millions
Werewolf Therapeutics Inc 1,815.69%$ 1,815.686 millions
Bicycle Therapeutics Plc1,665.68%$ 1,665.680 millions
Longeveron Inc 1,363.64%$ 1,363.636 millions
Chimerix inc 1,340.00%$ 1,340.000 millions
Aethlon Medical Inc 964.89%$ 964.887 millions
Phathom Pharmaceuticals Inc 857.14%$ 857.143 millions
Lftd Partners Inc 842.55%$ 842.554 millions
Mersana Therapeutics inc 826.09%$ 826.087 millions
Eyepoint Pharmaceuticals Inc 814.50%$ 814.504 millions
Pavmed Inc 802.86%$ 802.857 millions
Bionexus Gene Lab Corp 792.68%$ 792.683 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ESM's Profile

Stock Price

ESM's Financials

Business Description

Fundamentals

Charts & Quotes

ESM's News

Suppliers

ESM's Competitors

Customers & Markets

Economic Indicators

ESM's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071